RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07175220, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology

    Inclusion criterion 2

  3. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1

    Exclusion criterion 17

  4. ECOG score is 0 or 1

    Inclusion criterion 3

  5. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07175220, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age range of 18-75 years old (including both ends), gender not limited;
  • Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology
  • ECOG score is 0 or 1
  • Expected survival period ≥ 12 weeks
  • Has a good level of organ function
  • Patients voluntarily joined the study and signed informed consent

Exclusion Criteria:

  • Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
  • Symptomatic or active central nervous system tumor metastasis
  • Previously or simultaneously suffering from other malignant tumors
  • Spinal cord compression that cannot be cured by surgery and/or radiotherapy
  • Accompanied by uncontrolled tumor related pain
  • Plan to receive any other anti-tumor treatment during this trial period
  • Receive other anti-tumor treatments within 4 weeks before the first medication
  • Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration
  • Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
  • Moderate to severe pleural effusion with clinical symptoms
  • Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
  • Subjects who have experienced severe infections within 30 days prior to their first medication use
  • Administer attenuated live vaccine within 30 days before the first use of medication.
  • History of immunodeficiency
  • Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
  • History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
  • AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1
  • Untreated active hepatitis
  • Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • There are other serious physical or mental illnesses or laboratory abnormalities present

Quoted from ClinicalTrials.gov, NCT07175220, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07175220, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07175220